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	 University Hospital, Basel; and the Clinic of Orthopedic Surgery,
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The purpose of this prospective clinical study is to evaluate the role of combination chemother-
apy with rifampin in the treatment of orthopedic device—related infections in which the implant
could not be removed. Eleven patients with orthopedic implant-related infections due to staphylo-
cocci or streptococci were treated with the implant in situ. Each antimicrobial regimen included
rifampin in combination with a 19-lactam antibiotic or ciprofloxacin. The median duration of
treatment with rifampin was 86 days (range, 15-336 days) with a median follow-up of >24
months after cessation of therapy. Treatment was successful for 82% of patients. Failures were
associated with documented inappropriate treatment. These preliminary clinical data are sup-
ported by data from in vitro studies and animal experiments. Combination therapy with rifam-
pin, in particular rifampin and a quinolone, should be considered for patients with orthopedic
implant-related infections if the implant cannot be removed.
Long-term intravenous therapy combined with a one- or
two-stage replacement is frequently necessary for controlling
orthopedic device-related infection (ODRI) [1]. New antimi-
crobial regimens may cure infections that were previously
considered as necessitating removal of the device [2]. We
previously observed in an animal model that even short-term
treatment with rifampin can sterilize implant-related infec-
tions due to Staphylococcus epidermidis and Staphylococcus
aureus [3-5]. The present trial was designed as a pilot study
for evaluating whether a rifampin-containing regimen could
cure ODRIs rather than only suppress the clinical symptoms.
We applied such a regimen to 11 patients who had ODRIs
and from whom the device could not be removed.
We prospectively observed 11 patients (five women and
six men) with ODRIs due to gram-positive cocci who were
consulted by physicians from the Division of Infectious Dis-
eases (A.F.W. and W.Z.) of the University Hospital of Basel,
Switzerland, between September 1987 and July 1990. All
cases were referred by the orthopedic surgeon (A.G. or
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P.E.O.) who decided not to remove the implant because it
was needed for stabilization of a fracture or because it was
considered to be difficult to remove. Patients included in the
study met the following criteria for ODRI: (1) local pain; (2)
local signs of inflammation, and (3) isolation of gram-posi-
tive cocci from joint aspirates or intraoperative tissue that
were susceptible to rifampin. Included patients were periodi-
cally examined at least weekly during the first month of in-
fection and at least monthly thereafter. Patients with internal
fixation devices were observed every 3 months once clinical
cure was established for >1 year (cases 1-5 and 11, table 1).
For patients with prostheses at least bimonthly clinical visits
were continued until the time of this writing (>24 months,
cases 7-10) or until they died (case 6).
All 1 1 patients were treated with the implant in situ by the
standard antimicrobial regimen initiated by the attending
physician. After inclusion into the study, the patients re-
ceived their current antimicrobial regimen plus rifampin.
There was no control group because the orthopedic surgeon
referred patients only if the current state-of-the-art therapy
was most likely to fail. A treatment course of at least 2
months was planned. The upper limit of duration of treat-
ment was determined by the clinical and laboratory signs of
infection.
Patients were considered to be clinically cured if they suf-
fered from no or minimal pain, returned to the level of activ-
ity prior to the infection, and did not show signs of infection
on physical examination. Laboratory findings indicating
cure were defined as an erythrocyte sedimentation rate of
<30 mm/h or a C-reactive protein concentration of <20 mg/
L and a white blood count of <10,000/mm 3 . Endpoints of
the study were defined as follows. Success was defined as
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Table 1. Summary of data on characteristics and outcome of 11 patients with orthopedic implant—related infections due to staphylococci
or streptococci.
Case no. Age (y) Sex
Type of surgery
Microorganism
(type of infection)
Success with
therapy
Follow-up
(mo)Before infection (site) After infection
1 22 F Deep-wound infection
Intramedullary nail (femur) revision Staphylococcus aureus (acute) Yes >24
2 20 F Osteosynthesis (vertebra) Deep-wound revision S. aureus (acute) Yes >24
3 74 M Osteosynthesis
(acromioclavicular joint) Abscess puncture S. aureus (acute) Yes >24
4 42 M Debridement,
Osteosynthesis (clavicula) drainage S. aureus (acute) Yes >12
5 32 M Osteosynthesis (malleolus Drainage/partial
lateralis) removal S. aureus (hematogenous) Yes >12
6 76 F Knee prosthesis Drainage of the knee S. aureus (hematogenous) Yes >14
7 83 Group B streptococci
Knee prosthesis Arthroscopic lavages (hematogenous) Yes >24
8 86 Coagulase-negative staphylococci
Knee prosthesis Arthrocentesis (late) No N.A.
9 73 Coagulase-negative staphylococci
Knee prosthesis None (acute) Yes >24
10 59 M Knee prosthesis Arthroscopic lavage S. aureus (acute) Yes >24
66 F Two-stage Coagulase-negative staphylococci
Total hip prosthesis replacement (late) No N.A.
NOTE. N.A. = not applicable.
clinical cure and laboratory parameters indicating no signs of
infection >24 months after cessation of antimicrobial ther-
apy. Success was also defined as patient survival or no sched-
uled removal of the internal fixation devices >6 months after
clinical cure. If the internal fixation devices were removed,
negative results of culture of the whole device were required.
Failure was defined as the presence of clinical and/or labora-
tory signs of infection after cessation of antimicrobial ther-
apy. Antimicrobial therapy was guided by the MIC for the
infecting strain [6] and the presence or absence of #-lacta-
mase production. The antimicrobial regimen for all patients
except one (case 11) included rifampin within 6 days after
the start of antimicrobial therapy. Patient 1 I received mono-
therapy with ciprofloxacin before being referred to the In-
fectious Disease Service and being included in the study.
The median age was 66 years (table 1). Infections were
related to osteosynthesis material (cases 1-5), knee prosthe-
sis (cases 6-10), and hip prosthesis (case 11). Six patients
had acute implant-related infection after surgery, three had
hematogenous infection (case 5, during sporadic use of intra-
venous heroin; case 6, with no obvious source; and case 7,
following teeth extraction), and two had delayed infection
with 6- and 9-month duration of symptoms before adminis-
tration of the present antimicrobial therapy.
Treatment was successful for nine (82%) of 11 patients
(table 1). Failure of therapy was observed for two patients
who had delayed infection and for whom antimicrobial treat-
ment was considered inappropriate. The excellent success
rate in our study (82%) confirms data from in vitro and ani-
mal experiments [3, 4, 7, 8]. A recent study showed that a
cure rate of 90% can be achieved with combination therapy
with ofloxacin and rifampin [9]. Rifampin has excellent effi-
cacy in the treatment of ODRIs (these infections may be
cured), a property that correlates with its ability to eradicate
adherent and nongrowing staphylococci. Combination ther-
apy with ciprofloxacin and rifampin has recently been used
effectively as oral treatment of S. aureus right-sided endocar-
ditis [10]. Rifampin has good bioavailability, a relatively
long half-life (2.5 hours), and excellent activity against staph-
ylococci. However, because of the frequent emergence of
organisms that are resistant to rifampin, a second drug is
required for treatment of ODRIs.
The design of our study, the small number of cases, and
the lack of controls limit the external validity of the results.
However, the orthopedic surgeons referred patients to the
Infectious Disease Service only when their treatment options
were most likely to fail, thus introducing a potential bias
toward findings that contradict those of our own. Further-
more, this therapy does not preclude regular treatment, in-
cluding removal of the device if treatment with rifampin com-
binations fail. On the basis of these clinical results and the
encouraging data from in vitro tests and animal experiments
[3-5], a multicenter, double-blind controlled clinical trial
comparing regular antimicrobial treatment with and without
rifampin was launched in January 1992. However, with the
low incidence of such infections and the required follow-up,
the results of the study will not be published before 1996.
Until such data are available, the results of the clinical study
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presented herein (supported by in vitro data and animal ex-
periments) may contribute to the treatment options for
current patients for whom removal of the implant is not
feasible.
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